Clinical Trial Update: The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating a PARP inhibitor in combination with cisplatin and hyperthermia during interval cytoreductive surgery and HIPEC for ovarian …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Ovarian Cancer

Drugs mentioned

• PARP inhibitor

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Ovarian Cancer, Epithelial Cancer | Phase 1, Phase 2 | Status: RECRUITING